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Abstract: 
BACKGROUND: People with advanced heart failure have repeated hospital 
admissions. Advance care planning can support patient preferences, but 
studies in people with heart failure have not been assessed.    
AIM: To evaluate the literature regarding advance care planning and 
hospitalisation in heart failure.  
DESIGN: Systematic review and narrative analysis.(PROSPERO 
CRD42017059190)  
DATA SOURCES: Electronic databases were searched (1990 to 
23.03.2017); MEDLINE(R), Cochrane Library,  CINAHL, and Scopus. Four 
journals were hand searched. Two independent researchers screened 
against eligibility criteria.  One reviewer extracted all data and a sample by 
a second. Quality was assessed by Cochrane Risk of Bias or the Critical 
Appraisal Skills Programme Tool for Cohort Studies.    
RESULTS: 8/1713 articles were included representing 14,357 participants 
from in/outpatient settings from five countries. Two randomised-controlled 
trials and one observational study assessed planning as part of a specialist 
palliative care intervention; one randomised-controlled trial assessed 
planning in addition to usual cardiology care; one randomised-controlled 
trial and one observational study assessed planning in an integrated 
cardiology-palliative care model; one observational study assessed 
evidence of planning (advance directive) as part of usual care, and one 
observational study was a secondary analysis of trial participants coded Do 
Not Attempt Cardiopulmonary Resuscitation. Advance care planning i) 
reduced hospitalisation(5/7 studies), ii) increased referral/use of palliative 
services (4/4 studies), iii) supported deaths in the patient-preferred place 
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(2/2 studies).  
CONCLUSIONS:  
Advance care planning as part of a specialist palliative care care 
intervention reduces hospitalisation. Preliminary studies of planning 
integrated into generic care, accessing specialist palliative care support if 
needed, are promising.    
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Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.   
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.   
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).   
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I
2
) for each meta-analysis.  
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on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).   
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.   
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).   
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).   
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.   
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
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PALLIATIVE MEDICINE AUTHOR SUBMISSION CHECKLIST   
Please complete this checklist for all papers submitted. Please indicate, very briefly, how this has been addressed. This checklist is a 
mandatory upload on submission.  
Item Explanation How this has been addressed 
(briefly, a sentence will suffice) 
 
Article title WHY: Because we want readers to find your work. 
Have you followed our guidelines on writing a good title that will be found by search engines? (E.g. with 
methods in the title, use of common words for the issue addressed, no country names, and possibly 
indicating findings). If your study has an acronym is it included in the title? 
 
INCLUDED REVIEW TYPE AND 
MESH TERMS 
Abstract WHY: Because structured abstracts have more detail for readers and search engines. 
Have you followed our guidelines on writing your structured abstract? Please remember we have 
separate abstract structures for original research, reviews and case reports. There should be no 
abbreviations in the abstract, EXCEPT a study acronym which should be included if you have one. If a trial 
(or other design formally registered with a database) have you included your registration details? 
 
PLEASE SEE Pg1 
Key statements WHY: Because readers want to understand your paper quickly. 
Have you included our key statements within the body of your paper (after abstract and before the main 
text is a good place!) and followed our guidelines for how these are to be written?   There are three main 
headings required, and each may have 1-3 separate bullet points. Please use clear, succinct, single 
sentence separate bullet points rather than complex or multiple sentences.  
 
PLEASE SEE Pg2 
Keywords WHY: Because MeSH headings mean it is properly indexed. 
Have you given keywords for your study? We ask that these are current MeSH headings unless there is 
no suitable heading for use (please give explanation in cover letter).  https://meshb.nlm.nih.gov/search  
 
PLEASE SEE Pg2 
International 
relevance 
WHY: We have readers from around the world who are interested in your work.  
Have you contextualised your work for an international audience and explained how your work 
contributes to an international knowledge base?  Avoid drawing from policy from one context only, think 
how your work could be relevant more widely. Do define terms clearly e.g. hospice has a different 
SEE REFERENCES FROM SETTINGS 
ACROSS THE WORLD, STUDIES 
ARE DRAWN FROM USA, 
CANADA, ASIA, EUROPE, UK 
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meaning in many countries.  
 
Publishing 
guidelines 
WHY: Because clear and robust reporting helps people interpret your work accurately 
Have you submitted a completed checklist for a relevant publishing guideline as a supplementary file? 
http://www.equator-network.org/ These include CONSORT, PRISMA, COREQ checklists, but others may 
be more relevant for your type of manuscript. If no published checklist exists please create one as a table 
from the list of requirements in your chosen guideline. If your study design does not have a relevant 
publishing guideline please review closest matches and use the most appropriate with an explanation.  
 
YES – PRISMA 
Word count WHY: Because readers want to find the core information quickly. 
Does your paper adhere to our word count for your article type? Please insert number of words in the 
box to the right. Remember that tables, figures, qualitative data extracts and references are not included 
in the word count.  
 
4311 
Figures and tables 
and/or quotations 
WHY: Because readers want to find the core information quickly.  
Have you adhered to our guidelines on the number of tables and figures for your article type?  
 
Data (e.g. quotations) for qualitative studies are not included in the word count, and we prefer that they 
are integrated into the text (e.g. not in a separate table).  
 
Figure – 1 
Tables – 4 
(in article 1, online 3) 
Study registration WHY: Because this means readers understand how you planned your study 
Where appropriate have you included details (including reference number, date of registration and URL) 
of study registration on a database e.g. trials or review database. If your study has a published protocol, 
is this referenced within the paper?  
 
STUDY REGISTERED WITH 
PROSPERO SEE Pg4 
Other study 
publications? 
WHY: So readers can understand the full context of your study 
If there are other publications from this study are these referenced within the body of the paper? Please 
do not reference papers in preparation or submitted, but in-press publications are acceptable.  
 
NO 
Scales, measures or 
questionnaires 
WHY: So readers can understand your paper in the context of this information 
If your study primarily reports the development or testing of scales/measures or questionnaires have 
you included a copy of the instrument as a supplementary file?  
 
NA 
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Abbreviations WHY: Because abbreviations make a paper hard to read, and are easily misunderstood 
Have you removed all abbreviations from the text except for extremely well known, standard 
abbreviations (e.g. SI units), which should be spelt out in full first? We do not allow abbreviations for 
core concepts such as palliative or end of life care.  
 
YES 
Research ethics 
and governance 
approvals for 
research involving 
human subjects 
WHY: We will only publish ethically conducted research, approved by relevant bodies 
Have you given full details of ethics/governance/data protection approvals with reference numbers, full 
name of the committee(s) giving approval and the date of approval?  If such approvals are not required 
have you made it explicit within the paper why they were not required. Are details of consent 
procedures clear in the paper? 
 
SYSTEMATIC REVIEW – NO 
ETHICS REQUIRED 
Date(s) of data 
collection 
WHY: So readers understand the context within which data were collected 
Have you given the dates of data collection for your study within the body of your text? If your data are 
over 5 years old you will need to articulate clearly why they are still relevant and important to current 
practice.  
 
DATABASE SEARCHES WERE 
FROM 23/3/17 to 30/6/17 
INCLUDED STUDIES FROM 1990 
to 30/6/17 
Structured 
discussion 
WHY: So readers can find key information quickly 
Papers should have a structured discussion, with sub headings, summarising the main findings, 
addressing strengths and limitations, articulating what this study adds with reference to existing 
international literature, and presenting the implications for practice.  
 
SEE Pg10-13 
Case reports WHY: So that participants are protected, and its importance made clear 
If your study is a case report have you followed our clear structure for a case report, including 
highlighting what research is needed to address the issue raised?  Have you made clear what consent 
was required or given for the publication of the case report? Have you provided evidence of such 
consent as a supplementary file to the editor?  
 
NA 
Acknowledgements 
and declarations 
WHY: So readers understand the context of the research 
Have you included a funding declaration according to the SAGE format?  Are there acknowledgements to 
be made? Have you stated where data from the study are deposited and how they may be available to 
others? Have you conflicts of interest to declare? 
 
NO FUNDING 
Supplementary WHY: So the context is clear, but the main paper succinct for the reader ONLINE TABLE 3 – MEDLINE 
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data and materials Is there any content which could be provided as supplementary data which would appear only in the 
online version of accepted papers? This could include large tables, full search strategies for reviews, 
additional data etc.  
SEARCH 
References WHY: So people can easily find work you have referenced 
Are your references provided in SAGE Vancouver style? You can download this style within Endnote and 
other referencing software. 
 
YES 
Ownership of 
work.  
Can you assert that you are submitting your original work, that you have the rights in the work, that you 
are submitting the work for first publication in the Journal and that it is not being considered for 
publication elsewhere and has not already been published elsewhere, and that you have obtained and 
can supply all necessary permissions for the reproduction of any copyright works not owned by you. 
 
YES 
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TITLE 
Does advance care planning in addition to usual care reduce hospitalisation for patients with 
advanced heart failure: A systematic review and narrative synthesis. 
 
ABSTRACT 
BACKGROUND: People with advanced heart failure have repeated hospital admissions. Advance care 
planning can support patient preferences, but studies in people with heart failure have not been 
assessed.     
AIM: To evaluate the literature regarding advance care planning and hospitalisation in heart failure. 
DESIGN: Systematic review and narrative analysis.(PROSPERO CRD42017059190) 
DATA SOURCES: Electronic databases were searched (1990 to 23.03.2017); MEDLINE(R), Cochrane 
Library,  CINAHL, and Scopus. Four journals were hand searched. Two independent researchers 
screened against eligibility criteria.  One reviewer extracted all data and a sample by a second. 
Quality was assessed by Cochrane Risk of Bias or the Critical Appraisal Skills Programme Tool for 
Cohort Studies.   
RESULTS: 8/1713 articles were included representing 14,357 participants from in/outpatient settings 
from five countries. Two randomised-controlled trials and one observational study assessed planning 
as part of a specialist palliative care intervention; one randomised-controlled trial assessed planning 
in addition to usual cardiology care; one randomised-controlled trial and one observational study 
assessed planning in an integrated cardiology-palliative care model; one observational study 
assessed evidence of planning (advance directive) as part of usual care, and one observational study 
was a secondary analysis of trial participants coded Do Not Attempt Cardiopulmonary Resuscitation. 
Advance care planning i) reduced hospitalisation(5/7 studies), ii) increased referral/use of palliative 
services (4/4 studies), iii) supported deaths in the patient-preferred place (2/2 studies). 
CONCLUSIONS: 
Advance care planning as part of a specialist palliative care care intervention reduces hospitalisation. 
Preliminary studies of planning integrated into generic care, accessing specialist palliative care 
support if needed, are promising.   
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KEY STATEMENTS 
What is already known about the topic? 
• Advance care planning can support patient care preferences in the event of deterioration  
• Studies of advance care planning in people with heart failure have not been assessed.     
What this paper adds? 
• Studies of advance care planning as part of a specialist palliative care care intervention show 
benefit with regard to supporting patient-preferred place of care and death and reduction in 
hospitalisation 
• There is only low quality evidence for advance care planning delivered as a single 
component in this patient group. 
Implications for practice, theory or policy? 
• Referral of all patients with heart failure to specialist palliative care in order to receive 
advance care planning is non-sustainable and unnecessary 
• Findings from studies where advance care planning is integrated into generic care, with 
access to specialist palliative care support if needed, are promising and should be further 
tested. 
KEYWORDS 
Heart Failure 
Advance Care Planning 
Admissions 
Readmissions 
Palliative 
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INTRODUCTION 
 
Despite effective treatments, heart failure remains a terminal condition with a high mortality and 
morbidity.(1, 2) Although there is increasing awareness of the significant symptom burden and 
palliative care needs of people with advanced heart failure, repeated hospital admissions, 
emergency department attendance and death in hospital are experienced by many.(3-5) Compared 
to people with advanced cancer, people living with heart failure have less understanding of their 
condition, including stage of disease, less involvement in clinical decisions about their care, 
especially towards the end of life and less access to supportive and palliative care services.(6, 7) An 
unpredictable illness trajectory with difficult prognostication and fragmented care are cited as 
reasons for these observations. (8-10)  Although integrated services (11) which aim to improve both 
general and specialist palliative care support to these patients are developing, this is not 
implemented routinely in all services.   
A recent consensus statement defines advance care planning as that which: “… enables individuals 
to define goals and preferences for future medical treatment and care, to discuss these goals and 
preferences with family and health-care providers, and to record and review these preferences if 
appropriate” .(12) Patients can express wishes about their care to their treating team and family 
members at the time, and assist decision making when they are no longer able to have those 
conversations themselves.(13) These include simple direct orders such as “do not attempt 
cardiopulmonary resuscitation” decisions, and complex planning discussions including; treatment 
goals, ceilings of treatment, and preferences regarding place of care or place of death.  
 
Evidence to date indicates that advance care planning is acceptable with likely benefit to individuals, 
families and the healthcare system. Although there is no full health economic evaluation there is 
emerging evidence of cost savings especially for people with diseases associated with high end-of-
life healthcare costs. (14, 15) Brinkman-Stoppelenburg’s systematic review of 113 papers concluded 
that advance care planning improved support for patients’ end of life wishes, increased hospice use 
and reduced hospital admission but few papers measured clinical outcomes and none reported any 
safety measures.(16) A similar issue is apparent in a more recent review of advance care planning in 
older adults, (17) where most studies did not use a standardised advance care planning, measure 
impact on quality of life or health service use.  People with heart failure have recognised high costs 
at the end-of-life, mainly driven by hospital admission. Therefore, advance care planning could be an 
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effective and cost-effective way to support people with advanced heart failure in preferences for 
care and place of death at the end of life.  
Objectives 
The primary objective of this study was to assess whether advance care planning, in addition to 
usual care, reduces the number of hospital admissions for patients with advanced heart failure. The 
secondary objective was to assess whether advance care planning, in addition to usual care, 
improves adherence to patient preferences in care, patient-reported outcomes, place of death and 
satisfaction with care in this patient group.  
METHODS 
A systematic review was performed using Cochrane methods and reported in accordance with the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).  The protocol was 
registered with PROSPERO, Centre for Reviews and Dissemination, York University 
(CRD42017059190).  
Search strategy 
The following databases were searched from 1990 until 23.03.2017:  Ovid MEDLINE(R), Cochrane 
Library; Cochrane Central Register of controlled trials (Central), Methods Studies, CINAHL, and 
Elsevier Scopus. No language limits were applied.  MeSH terms and text words for heart failure and 
advance care planning and their synonyms were combined. Terms were adapted for each database 
(see online table 3 for MEDLINE search). Reference lists of retrieved articles were scanned. The 
contents of the following journals were manually reviewed from 2015 to 2017; Journal of Palliative 
Medicine, Palliative Medicine, Journal of Pain and Symptom Management, BMJ Supportive and 
Palliative Care and Circulation. Experts in the field were contacted to ensure important studies 
included.  
Eligibility criteria 
Population: Studies included those with participants with  all causes and classifications of heart 
failure (preserved systolic function included). In the absence of an agreed biomarker, advanced 
heart failure was based on clinical NYHA report (class III or IV).  Studies involving paediatric, cardiac 
transplant and Left Ventricular Devices were excluded.  
Intervention: Studies were required to name the intervention as containing; advance care 
planning/directive, living will, medical directive, resuscitation order/plan, end of life order/plan, 
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anticipatory care plan or medical treatment plan.  Studies addressing ‘patient centred care’ only, 
without any of the above terminology or framework were excluded.  
Comparator: The comparator was usual care however defined.   
Outcome: The primary outcome was hospital admissions including number of hospital admissions 
(all cause and heart failure cause), number of hospital re-admissions, and rate of hospital 
admissions. The secondary outcomes were ; health utilisation other than admission to hospital 
(Emergency department presentation, local doctor, hospice, and community palliative care), place of 
death, death in preferred location, patient and family satisfaction.  
Design: The study design criteria were broadened after initial screening searches due to the limited 
scope of literature on this area. Study designs included were; randomised control trials, quasi-
experimental studies, and single arm observational studies.  Due to small number of results, neither 
the outcome nor the study design were applied to the search.  
Study selection 
Study abstracts, titles and full texts, where necessary, were screened independently by two 
reviewers against the inclusion/exclusion criteria. Any discrepancies unresolved by discussion 
between reviewers were adjudicated by a third reviewer. Studies that matched the selection criteria 
were retrieved and their full text version analysed.    
Data extraction 
A standard data extraction tool was piloted on two papers, then used to extract data from the 
included studies. A second reviewer extracted data using the tool in 25% of studies. Data were 
extracted in relation to study identifiers, design, setting, population, intervention, control and 
outcomes. Further information documented included funding, key conclusions, references and any 
questions to find out from authors.  The Cochrane Risk of Bias Tool (18) was used to assess bias in 
the randomised trails and the Critical Appraisal Skills Programme Tool for Cohort Studies (19) was 
used to assess bias in the non-randomised trials. Quality was not used as an exclusion criterion, but 
was taken into account in the analysis of the findings. 
Analysis 
A narrative summary with descriptions, comparisons and limitations of the studies was completed. 
Meta-analysis of combined data was not possible due to study heterogeneity with regard to 
population, intervention, comparator and outcome.   
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RESULTS 
Selected studies 
Out of 1713 titles, eight papers (four RCTs and four cohort studies), met the eligibility criteria. Figure 
1 shows the PRISMA selection flow chart and Table 1 shows the characteristics of included studies.  
FIGURE 1: PRISMA Flow sheet 
TABLE 1: STUDY CHARACTERISTICS  
Setting and Population 
Included studies were conducted in USA (3 studies), UK (2 studies), Canada (1 study), Sweden (1 
study) and Hong Kong (1 study). Patients were enrolled from the community (2,426 patients) and 
inpatient (11,931 patients) settings. Overall, studies represented 14,357 participants (mean age 
75yrs, total range not provided, men 58%).  The median study size was 138 participants (range 72 
participants (20) to 8339 (21)).   Heart failure was the primary diagnosis in 8 studies, 1 study (22), 
included patients with acute coronary syndromes and heart failure.  Five papers gave NYHA class on 
enrolment; >92% of study participants had class II-IV.  The rate of co-morbid chronic disease was 
high, mean percentage with  Diabetes Mellitus across six studies was 38% (range 18% -53%), mean 
percentage patients with Renal Impairment 53% (range 22% - 77%).  
Design 
Three of the four RCTs were designed with sufficient power to evaluate effectiveness, (20, 23, 24) 
one was a feasibility trial (22) and only one was multi-site. (23)  Only one recruited from the 
ambulant patient population. (20)  Of the four observational studies, one was secondary analysis of 
trial data, McAlister (21),  two were large retrospective cohorts (25, 26) and one a small two-site 
prospective cohort. (27) 
Types of interventions and Comparators: 
Two RCTs (23, 24) and one observational study (25) assessed advance care planning as part of a 
multi-disciplinary specialist palliative care intervention.  One RCT assessed advance care planning in 
addition to usual cardiology care (22) and one observational study assessed evidence of advance 
care planning (advance directive documentation) as part of usual medical care (26). Two studies, one 
RCT (20) and one observational study (27), assessed advance care planning as part of an integrated 
cardiology-palliative care multi-disciplinary team model.  The eigth study was a secondary analysis of 
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trial data observing the relationship between cardiopulmonary resuscitation code status with clinical 
outcomes. (21) 
In most studies, advance care planning was only one part of a specialist palliative care, or integrated 
cardiology-palliative care intervention, and was not described specifically. In the feasibility RCT, (22) 
where advance care planning was the focus of the intervention, a description was provided 
(duration, timing and number of visits and by whom; production of a future care plan; nurse 
telephone support as needed) but not in the detail required to identify whether it included the 
elements recommended by Reitjens et al in their (12) consensus statement.  In Butler et al (26), no 
detail was given about the process whereby patients had received an advance directive or not. 
However, it was apparent that patients could receive an advance directive even if they were not 
under the care of a palliative physician, thus implying this was part of generic practice. No details 
were given about any other aspect of advance care planning. In the secondary data analysis, (21) 
detail was given regarding how the DNR orders were classified, but no information was given about 
the process of identifying goals of treatment.   
All four RCTs compared the intervention to usual care, three with a parallel group design and one 
(22) using a wait-list design. The observational studies used a mixture of comparators including: 
usual care, and no advance directive or full code status. One (27) had no study comparator but 
related findings to national data. Usual care descriptions lacked information regarding care received 
including the discipline of those caring for them, and the likelihood of receiving advance care 
planning or palliative care involvement as part of usual practice.   
Outcome measures 
The main study outcomes are described below: 
Health service utilisation 
Hospital admission/readmission were measured in seven studies.  The collection of data differed in 
both periods measured and whether discrete episodes or ‘each night admitted’ was the outcome. 
The time period ranged from 12 weeks,  through to 5 years (26).  Four studies showed reduction in 
hospital admission/readmission, including in two of the larger RCTs; mean average readmissions in 
the advance care planning group at 6 months of 0.42 compared to 1.47 in the control group (p = 
<0.09), reduced relative risk of readmission in the advance care planning group ( 0.55, CI 0.35-0.88) 
(23). Denvir et al (22) found no difference in number of hospital admissions, but nights spent in 
hospital were fewer in the early intervention group (Early 8.6 (15.3) vs Delayed 11.8 (17.1), p = 0.01).  
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Amongst the observational studies, two studies (25, 26) found a reduction in hospital admission, but 
this only reached statistical significance in Butler et al (p<0.001 over 5 years).(26)  
 
Two studies reported place of death data; both found increased deaths in preferred location and 
increased out of hospital deaths (home, nursing home or hospice) with advance care planning than 
known baseline estimates. (22, 27) Numbers of deaths in Denvir et al are too small to draw 
conclusion, but Johnson et al showed preferred place of death achieved in 61%, and hospital deaths 
in just over 40% compared with national figures of 82%. (27)  
Hospice use increased in advance care planning groups in all studies where specialist palliative care 
services were not part of the intervention anyway. (21, 22, 26) Participants with evidence of advance 
planning were more likely to have participated in hospice. (21, 25-27) Butler (26) and McAlister (21) 
showed patients with evidence of advance planning had an increased likelihood of discharge to 
hospice compared to those without: McAlister (21) (5% vs 1% (p<0.001)), Butler (26) (22.3% vs 6.4% 
(p<0.001)).  (see table 1)    
A cost-effectiveness analysis was done as part of the Brannstrom et al RCT (28). The intervention 
arm had a higher staffing cost; mean General Practitioner cost per participant 457 Euro compared 
with 224 Euro (p=0.00), other medical professional cost 1890 Euro compared with 189 Euro (p=0.00).  
This was, however, offset by a reduction in emergency hospital and transport costs.  Emergency 
transport cost per participant 98 Euro compared to 418 Euro (p=0.004) and mean hospital cost per 
participant 1632 Euro compared with 4896 Euro (0.009).  The overall net cost analysis was a saving 
of 49,000 Euro in the intervention group at 6 months.   
Patient-report measures 
Patient-report measures (quality of life and symptom assessment) were included in the RCTs but 
varied across the trials thus contributing to heterogeneity. The different tools employed included: 
McGill quality of life questionnaire-Hong Kong (MQOL-HK), Chronic Heart Failure Questionnaire-
Chinese version (CHQ), McGill Quality of heart failure scale (Chinese version), Edmonton Symptom 
Assessment Scale (ESAS), Kansas City Cardiomyopathy Questionnaire (KCCQ), Functional Assessment 
of Chronic Illness Therapy Palliative Care Scale (FACIT-pal), Functional Assessment of Chronic Illness 
Therapy Spiritual Wellbeing Scale (FACIT-Sp), Hospital Anxiety and Depression Score (HADS anxiety 
and depression), EQ5D heath thermometer and Visual Analogue Scale (VAS) and Essler 
Questionnaire.  
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Advance care planning improved QoL although only Rogers et al (24) had a sample size estimation 
solely based on QoL measures as the primary outcome. Rogers et al found a clinically and statistically 
significantly improved KCCQ (9.49 points, 95% CI:0.94 to 18.05, p = 0.030;) and for FACIT–Pal (group 
difference in favour of intervention; 11.77 points, 95% CI: 0.84 to 22.71, p = 0.035).(24) The clinical 
important difference for the FACIT-Pal has not been formally evaluated,  but is estimated at 9 points. 
(29, 30) Brannstrom et al did not find a significant difference in overall KCCQ-12 score, but the QoL 
summary score was better in the intervention group (49.5 SD 24.7 vs 61.3 SD 26.6 p= 0.047). This 
team also found greater improvement in age-adjusted delta-value of EQ5D from baseline to 6 
months in the intervention group (p=0.02).(20) Wong et al found improvement favouring 
intervention in the McGill QOL (6.16 (0.44) [UC] vs 7.37 (0.29); p<0.001) and total CHFQ scores (4.47 
(0.23) [UC] vs 5.26 (0.17) (UC); p<0.001). (23) Both differences are highly statistically significant, but 
the clinically important difference for the McGill and total CHFQ (unlike for subscales) is unknown.   
 
Symptoms improved in the three larger RCTs. In Wong et al, the ESAS summary score improved 
more with intervention than control (73% vs 41.4% [UC], p<0.05) with statistically and clinically 
significant improvement in the CHFQ dyspnoea and mastery domains (dyspnoea 4.89 (0.28) (UC) vs 
5.82 (0.019), p< 0.001; mastery 4.64 (0.26) (UC) vs 5.36 (0.22, p< 0.001).(23) No statistical difference 
was found in ESAS measures in Brannstrom et al (20) but NYHA class (symptom based) improved for 
36% in the intervention group compared with 9% in usual care (p= 0.015). Rogers et al did not report 
KCCQ symptom domains, but depression (─1.94 points; p = 0.020), anxiety (─1.83 points; p = 0.048) 
and spiritual wellbeing (3.98 points; p = 0.027) improved in the intervention group compared with 
usual care. (24) 
Denvir (22), showed no significant difference between intervention and usual care  for symptoms 
(ESAS) or QoL (EQ5D) but was not designed to show effect for any outcome.  
Quality assessment  
The four RCTs were of moderate quality with low risk of bias for selection, attrition and reporting 
biases, but high risk for performance and detecton biases. The sample size, where stated, was 
reached in all RCTs to reach adequate power. (20, 23, 24) Of note, Denvir et al was not designed to 
assess effectiveness but the Cochrane risk of bias tool does not assess statistical power. The high risk 
of performance and detection bias was due to non-blinding of participants, providers; unavoidable 
due to the nature of the intervention.  However, the researchers collecting outcome assessments 
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was unblinded, or unclear. This risks potentially avoidable reporting bias as patient reported 
outcomes included subjective quality of life and symptom measures.  
The observational studies included well recruited cohorts with objective outcomes. The quality, 
however, was reduced by risk of information bias, insufficient follow up and the impact of potential 
confounders impacting the results.  
The quality assessment details can be found on the online tables 1 and 2.  
Generalisability 
The population studied was representative of the advanced heart failure population. The patients 
had symptomatic disease and co-morbidity.  Denvir et al (22) also included patients with a recent 
acute coronary syndrome.  The four RCTs were set in the outpatient setting or in conjunction with 
discharge planning which is a clinically appropriate timeframe. However, only one study was multi-
site, hence application across different settings has not been consistently shown. In two RCTs the 
intervention was completed by one set of facilitators only (nurse practitioner, doctor), hence 
duplication by different individuals is needed. However, the advance care planning intervention was 
insufficiently described to apply elsewhere and multi-site data from involving multiple practitioners 
are needed. 
Table 2 depicts outcomes by whether advance care planning was delivered as a single component in 
general clinical care or as part of a specialist palliative care delivered intervention. Patient-reported 
measures such as symptom control and quality of life were only measured when advance care 
planning was delivered as a component of specialist palliative care, apart from the feasbility RCT of 
advance care planning. In turn, measures specifically relating to the advance care planning 
component (concurrence with expressed preferences at the end of life, place of death) were not 
measured in the specialist palliative care trials where the focus was quality of life and symptom 
control. 
DISCUSSION 
This systematic review synthesises current evidence to show that, for the population with advanced 
heart failure,  when delivered as part of a specialist palliative care or cardiology-palliative integrated 
team  intervention, advance care planning changes patterns of health service utilisation. Advance 
care planning increases hospice use, reduces hospital use and supports patients in their preferred 
place of care and death.  This evidence is derived from study populations with high levels of co-
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morbidity, consistent with the wider advanced heart failure population, where co-morbidity is 
common.  
Our data also show that advance care planning delivered as part of a specialist palliative care 
intervention or integrated team improves symptoms and quality of life. However, it is not possible to 
identify the contribution of the advance care planning component. The studies of advance care 
planning alone were either not designed to show effectiveness (22), or did not measure patient-
reported outcomes (21, 26). Advance care planning as the only additional care component may 
improve QoL by helping those who wish to, to stay out of hospital, and improve even difficult 
symptoms indirectly by facilitating access to specialist palliative care. Advance care planning 
therefore seems well placed as a core skill for non-specialist palliative care clinicians, supported by 
specialist palliative care services for education, training and clinical support as needed. In order to 
embed advance care planning effectively into routine practice cardiology services may need to be 
reconfigured and staff trained to conduct advance care planning, become proficient in advanced 
communication skills and in basic holistic assessment. Referral pathways with specialist palliative 
care and community services would ne d to be established.  Schellinger et al (25) describe the 
implementation of advance care planning in a large health care system delivered through a specialist 
palliative care service, but using the model of advance care planning within usual care much can be 
done within current resource. The interventions used in Brannstrom et al (20) and  described by 
Johnson et al (27) were integrated models drawing together existing cardiology and palliative care 
services, for example, in education, training and combined multi-disciplinary team meetings. Across 
England, pathways of care and mutual education between cardiology and palliative care seem to 
facilitate development of these required skills for heart failure nurses, and referrals to specialist 
palliative care if needed. (31) 
Advance care planning as part of routine care would help early identification of those who would 
benefit; careful preparation is needed if a person with a serious illness prefers to live and die at 
home.(32)  A UK based primary care study showed that people with heart failure are much less likely 
than those with cancer to be registered on the practice palliative care register (a mechanism 
whereby co-ordinated care for those at the end of life can be facilitated). (33)  Of those that were 
registered, a third were registered in the last week of life; a short timeframe to support death at 
home if preferred. 
Most health costs in advanced heart failure are driven by hospital admission and the use of invasive 
but futile interventions in the last weeks of life administered in hospital. Hence, place of care and 
death are financial and quality priorities for patients and the healthcare system alike. Only one study 
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(advance care planning as part of an integrated cardiology-palliative care intervention) evaluated 
healthcare costs; favouring intervention. These data are consistent with those from other advanced 
disease populations where involvement of multi-disciplinary specialist palliative care, which include 
advance care planning as a component of care, is associated with reduced healthcare costs at the 
end of life,(32, 34-36) and emerging data for advance care planning as a generic intervention.(15) As 
transfer of care to the community may have fewer visible costs, careful further financial analysis on 
interventions is needed, including those affecting family and friends. Health economic evaluation of 
interventions where advance care planning is used as a component of cardiology care rather than 
specialist palliative care is needed. Although providing less robust data, the included studies of 
advance care planning as part of usual care, supported by specialist palliative care as needed only, 
gave promising data. It is likely that the additional cost of the multi-disciplinary palliative care team 
is needed only those with the most complex and persistent needs, but the benefits of advance care 
planning would be applicable for all with advanced disease.  
 
Strengths and limitations 
This study has a number of limitations regarding the evidence: Firstly, the benefit from advance care 
planning alone, distinct from delivery as part of a specialist palliative care service cannot be isolated 
from the most robust data. The details of what elements of advance planning were included, or how 
it was conducted were not provided. Also, although blinding of participant and clinicians was not 
possible, those collecting outcome data did not appear to be blinded either which could have led to 
bias. Although only one trial was multi-site, the risk of contamination was not discussed. The data for 
advance care planning in routine care are promising,  but further testing is needed. Secondly, in the 
observational studies, many confounders were not addressed.  Lastly, although a significant number 
of patients are represented, there were few studies and meta-analysis was not possible due to the 
differences in population, intervention, comparator and outcomes 
Limitations relating to the systematic review are those inherent with the methods. Despite searching 
a range of sources we may have missed important papers. Only a proportion of studies had data 
extracted by two researchers. 
Implications for clinical practice 
In the light of the emerging evidence base in generic advance care planning studies and encouraging 
findings in this review advance care planning for people with advanced heart failure seems to be 
beneficial and possible to implement in routine practice. Advance care planning delivered as part of 
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specialist palliative care appears to be helpful in terms of hospital use, symptoms and quality of life. 
However, implementation of advance care planning by cardiology clinicians as part of usual care, but 
supported by specialist palliative care as needed, is an attractive approach as it would enable all 
patients with advanced heart failure to have the opportunity to have their preferences identified 
and supported where appropriate and possible. The relatively scarce resource of specialist palliative 
care would therefore be triaged for patients with complex and persistent concerns. However, issues 
regarding service configuration, staff training, resources and referral pathways need to be 
considered and the lack of robust evidence of effectiveness as a stand-alone component recognised. 
As with any complex intervention which requires ongoing training and support at individual clinician 
and organisational levels by expert facilitators there are inherent dangers about rolling out at scale. 
The risk is that the intervention is diminished to a mere document and divorced from the approach 
to care which provides the context and frame for that documentation. (37)  
Implications for research 
Given the limitations of the included studies, these data support rather than define a new standard 
of care for advance care planning for people with advanced heart failure. Multi-centre RCTs which 
take into account contamination, other confounders, cost-effectiveness and the implications for 
education, training, and scalability across whole health services should be conducted. Delivery of 
advance care planning by non-specialist palliative care services seems to be an attractice way 
forward, but questions regarding effectiveness when delivered as a single component, cost-
effectiveness and implementation remain.   
For both future research and clinical practice the European Association for Palliative Care’s position 
statement on advance care planning (12) provides a useful framework to ensure core elements are 
present and important outcome measures, especially those which identify clinical effectiveness in 
addition to merely noting the presence or absence of advance care planning documentation. In 
addition, measures of possible advance care planning -related harms should also be included in any 
trial such as, unresolved distress due to advance care planning, failure for hospital management 
where this would have been appropriate, beneficial and agreed by the patient, increased carer 
burden. 
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CONCLUSIONS 
Trials of advance care planning as part of a specialist palliative care care intervention show benefit 
with regard to supporting patient-preferred place of care and death and reduced hospital 
admission/time in hospital. Findings from studies where advance care planning is integrated into 
core cardiology care, with access to specialist palliative care support if needed, are promising and 
should be tested in future trials.   
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STUDY ID DESIGN/ 
SETTING 
POPULATION STUDY AIM INTERVENTION COMPARATOR OUTCOMES FINDINGS 
Randomised Controlled Trials:   *Sample size calculated to achieve 80% power at a significance level of 0.05  #Feasibility study, not powered for effect 
Wong et 
al 2016 
 
* RCT 
Multi-site 
Hong 
Kong 
Post DC 
 
N = 84  
INT = 43  
CONT = 41 
NHYA III-IV:  
89.3%  
Age:  
Mean 78.3  
SD 16.8 
Male 56% 
Mean DM 41% 
Mean CKD 52% 
To examine the 
effects of home-
based transitional 
PC program for 
patients with ESHF 
post hospital DC 
12 wk program post DC; 
Integrated SPC model,   
support from MDT  
ACP involves discussion of  
EOL issues and treatment 
preferences 
FU: 12months (reported to 
12wk) 
SPC based intervention  
UC: SPC medical 
clinic, DC advice 
and referral PRN 
 
 
 
Primary outcome 
4 wk adm  
 
Secondary 
outcomes: 
measured over 4 
and 12 wk, results 
for 12 wk,  
 
Adm Symptoms 
(ESAS), QOL  
(McGill, CHQ) 
 
Admissions:  
4 wk adm rate:   
INT 0.21 vs CONT 0.41 p=0.10 
12 wk adm rate: 
 INT 0.42 vs CONT 1.10 p=0.001 
RR of adm: 
 INT 4wk 0.81 (CI 0.51-1.27)  
INT 12 wk 0.55 (0.35-0.88)  
Symptoms 
Depression improved 
ESAS INT 45.9% vs CONT 16.1% p<0.05 
Dyspnoea improved 
ESAS INT 62.2% vs CONT 29% p<0.05 
Total improved ESAS INT 73% vs CONT 41.4% p>0.05 
QOL 
McGill: 6.16 SD 0.44 vs 7.37 SD 0.29 (UC); p<0.001 
CHQ: 4.47 SD 0.23 vs 5.26 SD 0.17 (UC); p<0.001 
Rogers et 
al 
2017 
*RCT 
Single-site 
USA 
Pre-Post 
DC 
N = 150 
INT =75  
CONT = 75 
NYHA III-IV 88% 
Age:  
Mean 71yrs 
SD not given 
Male 53% 
Mean DM 53% 
Mean CKD 77% 
To assess impact of 
ITP intervention on 
HF-related, and 
overall QOL in 
advanced HF 
Multicomponent, 
interdisciplinary, SPC 
intervention, with HF 
management 
Protocol driven physical 
symptom management, 
psychosocial and spiritual care, 
end of life preparation. ACP 
communication education for 
NP and discussion and 
documentation of AD 
(ongoing) 
FU: 3monthly for 4 years 
SPC based intervention 
 
UC: Cardiology 
driven MDT, 
standard HF 
management. PC 
consult PRN. 
HFN/Cardiology 
and GP FU 
Primary Outcome 
QOL (KCCQ, FACIT-
Pal) 
 
Secondary 
Outcomes 
Caregiver 
satisfaction,  
Cost utilisation  
Spiritual wellbeing 
(FACIT-Sp) 
Symptoms: (HADS) 
QOL  KCCQ: change from baseline at 24wk  
9.49 point diff (CI 0.94-18.05) p=0.03,  
FACIT-Pal: change from baseline at 24wk 
11.77 point diff (CI 0.84-22.71)p-0.035 
change at 12wk not given for either score  
but trend for less diff on graph 
FACIT-Sp: greater improvement in INT group                  
at 24w - diff 3.98 (CI 0.46-7.50)p=0.027 
Symptoms 
HADS-Dep: reduction greater in INT group at 24w  
difference  -1.94 (CI -3.57-0.31)p=0.020 
HADS-Anx: reduction greater in INT group at 24w  
difference  -1.83 (CI-3.64—0.02)p=0.048 
Admissions/mortality: No statistical difference  
in 6m mortality hospital adm rate 
Page 26 of 34
http://mc.http://mc.manuscriptcentral.com/palliative-medicine
Palliative Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Denvir et 
al 
2016 
Phase 2# 
RCT/ 
Wait-list 
design 
Single-site 
UK 
Pre-post 
DC 
N =100 
E =50   
D =50 
Elderly (>70),   
advanced heart 
disease  
(HF & ACS no 
NYHA data) 
Age:  
Mean 81yrs 
SD not given 
Male  60% 
Mean DM 38% 
Mean CKD 62%  
Assess the feasibility 
and acceptability of 
FCP in patients with 
advanced heart 
disease 
FCP: initial OPD with 
cardiologist and TN  
(trained in FCP principles) then 
2 HV with TN over 12 wk.  
Aim is to discuss and prepare 
FCP.  Record is given to 
patients, GP and after hours 
EHR. Focus on communication 
with service providers, patients 
and teams. (ACP = FCP)  
All patients received FCP either 
1
st
 12wk or 2
nd
 
 
FU: 24wk 
 
Cardiology based intervention 
DELAYED ‘D’ group 
had UC 1
st
 12 wks, 
then FCP 2
nd
 
12wks 
 
EARLY ‘E’ group 
had FCP 1
st
 12wk, 
then UC 2
nd
 12 wk 
UC not stated 
Primary Outcome 
HQRL at 12wk 
(EQ5D) 
Symptoms (ESAS),  
Psychological 
distress (Kessler 
questionnaire) 
 
Secondary 
Outcome-  
Healthcare usage  
Place of death and 
carer outcomes 
between 2 groups 
QOL 
EQ5D: no significant mean diff between 2 groups 
12wk (-0.01 CI -0.16,-0.13 p=0.86) or  
24wk (-0.07 CI -0.25,0.11p=0.44)  
EQ5D VAS: no diff between 2 groups at 12 or 24wk 
Symptoms 
ESAS: no statistical mean diff between 2 groups 
 at 12wk (0.62 CI -8.34,9.58, p0.89) or  24wk 
 (3.18 CI -6.90 13.26 p0.52) 
Admissions 
Significant diff in number of nights in hospital  
at 12wk E 2.7 (SD5.5) vs D 5.4 (SD9.4) p=<0.01  
and 24wk E 8.6(SD15.3) vs D 11.8(17.1) p=<0.01 
No diff in mean adm at 12wk E 0.5(SD0.9) vs  
D 0.4(SD0.6) p=0.6 or 24w E 0.8(SD1.3) vs  
D 0.7(SD0.7) p=0.54 
Mortality 
No difference in mortality at 12 or 24wk 
Place of death 
E: hospital 3/4(75%), home 1(25%) D: hospital 
1/3(33%) hospice 1(33%), care home 1 (33%), home 0  
No diff in carer distress scores between 2 groups. 
Brannstro
m et al 
2014 
*RCT 
Single-site 
SWEDEN 
OUTPT 
Home 
N=72, 
PREFER =  36 
UC =36 
HF NYHA III-IV 
100% 
Age: INT Mean 
81.9 SD 7.2 
CONT 
Mean 76.6 
SD10.2 
P=0.012  
Male 78.8% 
 
Mean DM = 
Evaluate outcomes 
of PREFER with 
regards to 
symptoms, HQRL 
and hospitalisation 
compared with UC 
PREFER: integrated 
interdisciplinary home based 
model combining community 
PC and cardiology teams to 
provide patient centred care. 
Team approach initially with 
physician and specialist nurse  
At 6m hand back to regular 
provider with management 
plan. 
ACP based on ESC principles, 
enrolment on PC registry, plan 
back to providers 
 
UC: GP or 
Medicine-Geriatric 
clinic FU 
Primary outcome: 
Symptom burden 
(ESAS), QOL 
(KCCQ-12, EQ-5D) 
and functional 
classes (NYHA)  
 
Secondary 
outcome: 
Hospitalisations 
and days spent in 
hospital 
QOL 
EQ-5D PREFER increased at 6m. The between group 
age-adj delta-value of HRQL baseline to 6m better for 
PREFER vs UC (p=0.02)  
Symptoms 
ii) KCCQ-12 Symptom summary scores were better  
in PREFER (55.9 SD 20.6 vs 65.8 SD 25.8, p=0.041) 
ESAS: no significant diff were found between groups. 
Numerical improvements were observed in 8/9 items 
in PREFER vs 4/9 in UC, Nausea improved PREFER 2.3 
SD 2.7 and not in UC 1.2 SD 1.7 (p0.0) 
NYHA improved at 6m PREFER 36% vs UC 9% (p0.015) 
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18% 
Mean CKD = 
65% 
FU: 6months 
 
Combined SPC and Cardiology 
intervention 
 
Admissions 
Mean hospitalisations less PREFER 0.42 SD0.60 UC 
1.47 SD 1.81 (p<0.009),  
Mean no days in hospital lower in PREFER  
2.9 SD 8.3 vs UC 8.5 SD 12.4 (p0.011) 
Costs 
Cost analysis: GP increased 16,468 euro for 296hr 
PREFER vs 8075 euro for 144hr UC 
Emergency transport decreased 3525 for 11 trips 
PREFER vs 15061 for 47 trips UC 
Other medical professionals increased 68103 for 
2381hr PREFER vs 6807 for 238hrs UC. Hospital care 
decreased 58793euro for 103 days PREFER vs 
176357euro for 309 days UC 
Observational studies 
Schellinge
r et al 
2011 
Retrospec
tive 
Cohort 
Multi site 
USA 
OUTPT 
N=1894 
DSACP =602 
No DSACP = 
1292 
NYHA not 
reported 
Age = 
81% >65y 
 
Male 49% 
Mean DM = 
43% 
Mean CKD = 
42% 
Describe the initial 
outcomes for the 1
st
 
2 yrs implementing 
DS-ACP for HF in a 
large health system 
DS-ACP: in-depth planning 
discussion for patients with 
advanced chronic illness, their 
chosen health agent +/-family. 
Proactive intervention to 
explore understanding of 
illness/fears gaps in 
information.  
ACP:Planning for 
complications and decision 
making with preparation of 
Statement of Treatment form 
as well as Advance Directives.  
 
FU: 2 years 
SPC based intervention 
Not stated 
 
Primary Outcome: 
ACP 
documentation on 
EHR.  
Inpatient or ED 
admission within 
30 or 60 days of 
referral 
 
Secondary 
outcomes: 
For those that 
died; hospice use, 
hospice LOS,  
Characteristics of 
those completing 
DS-ACP 
ACP documentation 
Health Directives: DS-ACP 94% vs no DS-ACP 24.8%  
p<0.001 
POLST: documented in DS-ACP 3.8% vs no DS-ACP 0% 
Statement of Treatment: DS-ACP only 84.8% vs 0% 
p<0.001 
Admissions 
Hospital Readm: Those who completed DS-ACP with 
30days of DC had reduced adm at 30 and 60 days vs 
those completed within 60days and no ACP. (Not 
statistically significant) 
ED Adm: no observable diff in ED attendance 
Hospice use 
Increased hospice use in DS-ACP 56.1% vs no DS-ACP 
37.3% p<0.002, No diff in hospice LOS 
OR for DS-ACP for hospice use 2.21 CI 1.3-3.7 p=0.03 
Type of referral was associated with participation in 
DS-ACP p>0.001 
Referrals from physicians/clinic (DSACP 40% vs 25.4%) 
or NCM (DSACP 30% v14.4%) compared with DC 
order (DSACP 23.9% vs 54.7%) 
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Johnson 
et al 
2012 
Prospectiv
e Cohort 
study 
2 sites 
UK 
OUTPT 
 
N=126 
Site 1(S1)=46 
Site 2(S2)=79 
NHYA II-IV = 
100% 
Age 
Mean = 78yrs 
SD10.7 
Gender 
Male 62 
(DM and CKD 
data not given) 
Describe care 
received by patients 
with advanced HF in 
two integrated 
teams with regard to 
place of death and 
evidence of advance 
planning 
Assessed both services for 
recognition of advanced HF 
close to death, evidence of 
EOLC in relation to POD, 
supportive and palliative care 
services accessed 
Site 1: MDT(Cardiology, PC), 
24/7 phone support, hospice, 
hospital beds, minimal nursing 
at home for dying patients 
Site 2: no formal MDT, back up 
cardiology/PC support,  
(increased services for dying 
patients at home) 
FU: 12 months 
Combined SPC and cardiology 
intervention 
National data  
And between two 
sites 
Primary Outcome: 
Evidence of 
recognition of 
advanced HF in 
people who died 
within 12m of 
referral 
Evidence of 
planning for EOLC, 
Supportive and PC 
services 
Recognition of those within 12 months of death 
Time from adm to service -> death longer in S2  
206 days vs 50 days S1 
Surprise question ->  death longer in S2  
171 vs 36 days S1; 
Surprise question agreed in 70%, 89% died in 12/12 
Evidence of ACP 
PPD known S1 78% S2 55% 
S2 higher PPD and actual POD home 25/39  
vs S1 10/30 (ACT/PREF) 
Hospice/palliative care service use 
SPC to death 77days S2 vs 29 days S1,  
Hospice deaths higher in S1 15/7 vs S2 6/5 
hospital deaths S2 32/2 vs S1 9/1 
SPC used in 72% in S1 and 34% S2 
McAlister 
et al 2015 
Retro-
cohort 
Multi-site  
CANADA 
INPT 
N=8339 
DNR = 2112 
CPR = 6227 
HF = 85%  
NYHA II-IV 
Age  
Mean =77yrs  
SD not 
recorded 
Male 51%  
Mean  
DM = 34% 
CKD: % eGFR 
<30 mL/min = 
22 
Explore the 
associations 
between DNR 
designations, quality 
of care and 
outcomes 
Used patient data from the 
EFFECT trial to perform chart 
review comparing those with 
DNR designation to those for 
full resuscitation (CPR)  
 
EFFECT: Enhanced Feedback 
For Effective Cardiac 
Treatment 
Population Cluster Randomised 
trial involving 86 hospitals with 
acute admissions for AMI or 
acute HF.  
 
Use of secondary trial data 
Comparison 
between DNR and 
CPR 
Primary Outcome: 
Examine the DNR 
order in 
hospitalised HF pts  
Examine the 
association 
between DNR 
orders and and 
outcomes  
 
Secondary 
Outcome: 
Difference in 
quality of care 
between DNR and 
CPR 
N=6227, 1220 DNR on admission, 892 changed to 
DNR during admission 
Characteristics of those with DNR 
DNR older 85yrs SD8 vs 74yrs SD 12 p<0.001, more 
likely to be female 68% vs 57% p<0.001, live in aged 
facility 49% vs 5% p<0.001, have Dementia 32% vs 5% 
p<0.001 
Service use 
DNR > DC to continuing care or palliative care unit 
5%vs 1%, or aged facility 41% vs 6% p<0.001 
Medications as measure of ideal treatment less 
frequent in DNR group 
ED visit at 30 days same 
Mortality 
DNR Higher 30 day mortality 15% vs 3% p0<0.001, 6m 
mortality 37% vs 13% <0.001 and 12m mortality 49% 
v 21% p<0.001 
Admissions 
All cause readmission at 30 days, 6m, 12m same 
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Butler et 
al 
2015 
Retro-
cohort 
Single –
centre 
USA 
INPT 
Primary 
diagnosis HF 
3592;  
with AD 413, 
no AD 3179 
Primary or 
comorbid HF 
NYHA not  
reported 
Age  
Mean 63.9yrs  
SD 15.9 
Male 56% 
DM not stated 
CKD: 
creat>2.75mg/
dl 15.6% 
Assess frequency 
and correlates of 
documented AD 
among hospitalised 
HF patients 
Retrospective case file review 
of all patients admitted to 2 
hospitals with primary or 
secondary diagnosis of HF to 
assess presence of AD. The 2 
units shared online medical 
record, which recorded AD and 
full medical history.  
Follow up 5 years 
 
Intervention based on usual 
medical care 
No AD Primary Ouctome: 
Prevalence of AD 
in EHR during or 
before adm 
 
Secondary 
Outcomes: 
Time to creation of 
AD, Characteristics 
of those with AD 
Mortality  
Admissions  
Primary HF patient analysis only used: 
Prevalence of AD 
11.5% had AD documented 
Patient characteristics AD less common in African 
American descent 42.9% vs white 56.1% p<0.01 
Increased rate of AD in more affluent 42.4% vs 28.6% 
lowest p<0.001   
Mortality 
Higher in-hospital mortality in AD 9.9% vs 4.5% 
p<0.001 
Hospice use 
Higher rate DC to hospice AD 22.3% vs 6.4% p<0.001 
Admissions 
No of readm over 5 years:  
Initially reduction year 1: AD 37.7% vs 58%, Years 2-3 
increase: AD 40.4% vs 27.4% 
Then reduction years 4-5: AD 26.9% vs 14.6% 
(p<0.001) 
Overall: N = 14,357, Age (Mean) 75yrs, Male = 58%, mean DM = 38%, estimated average CKD = 53% 
ACP = advance care planning, ACS = recent acute coronary syndrome, ACT = actual, AD  = advance directive, adm = admission/ admitted, , AMI = acute myocardial infarct, 
Brad = Bradford and Airedale HFNS, CHQ = chronic heart failure questionarie – Chinese version, CI = confidence interval, CKD = Chronic Kidney Disease, CONT = control, 
creat = creatinine, CPR = cardiopulmonary resuscitation, D = delayed or control group, DC = discharge, diff = difference, DM = diabetes , DNR = do not resuscitate, DS-ACP = 
Disease Specific Advance Care Planning, E = Early or Intervention group, ED = emergency department, eGFR = estimated glomerular filtration rate, EHR = Electronic Health 
Record, EOL = end of life, EQ5D = EQ5D quality of life scale, EQ5D VAS = EQ5D visual analogue scale, ESAS = Edmonton Symptom Assessment Scale, ESC = European Society 
Cardiology, ESHF= end stage heart failure, FACIT-Pal = Functional Assessment of Chronic Illness Therapy Palliative Care Scale, FACIT-Sp = Functional Assessment of Chronic 
Illness Therapy Spiritual Wellbeing Scale, FCP = future care planning, FU = follow up, GP = general practitioner, HADS- Anx = Hospital Anxiety Score, HADS – Dep = Hospital 
Depression Score, HF = heart failure, HQRL = health related quality of life, hr = hours of practice, HV = home visit, INPT = inpatient, INT = intervention, ITP = interdisciplinary 
palliative care, KCCQ = Kansas City Cardiomyopathy Questionnaire, LOS = length of stay, m = months, McGill = McGill Quality of Life questionnaire;Hong-Kong, MDT = 
multidisciplinary team, med = medication, mx = management, N = total number participants, NYHA = New York Heart Association rating of heart failure, OPD = outpatients 
department review, OR = Odds Ratio, OT= occupational therapist, OUTPT = outpatient, NCM  = nurse care manager , NP = nurse practitioner, PC = palliative care, , p/c = 
phone call or telephone follow up, POD = place of death, POLST = Physician Orders for Life Sustaining Treatment, PPD = preferred place of death, PREF = preferred, PRN = 
as required, Prov = provider(s), PT = physiotherapist, QOL = quality of life, Readm = readmissions, RCT = randomised control trial, RR = relative risk, Scar = Scarborough 
HFNS, SD = standard deviation, SPC = specialist palliative care, TN = trial nurse, UC = usual care, UK  = United Kingdom, USA = United States of America, wk = weeks, yrs = 
years 
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Records identified through database  
CINAHL;48 SCOPUS;1558 
MEDLINE; 132 COCHRANE;172 
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Additional records identified through 
other sources n=6 
Records after duplicates removed n=1713 
Abstracts included for screening n = 681 
Records excluded by Title 
screening n = 1032 
Full-text articles assessed for eligibility n = 180 
Records excluded by Abstract 
screening n = 501 
Studies included in qualitative synthesis n= 8 
 
Full text excluded due to: 
DESIGN: n =95  
POPULATION: n = 27 
INTERVENTION: n = 40 
OUTCOME: n = 10  
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Online Table 1. Quality assessment randomised controlled trials 
  
STUDY SELECTION 
BIAS/  
ALLOCATION 
BIAS 
PERFORMANCE 
BIAS 
DETECTION 
BIAS 
ATTRITION BIAS REPORTING 
BIAS 
OTHER  
Wong, 2016 LOW  
Randomisation 
by “Research 
Randomiser” 
HIGH 
Neither 
subjects nor 
providers 
blinded due to 
structure of 
design  
HIGH  
Neither 
providers nor 
researchers 
blinded due to 
structure of 
design 
LOW  
All subjects 
accounted for 
LOW 
 All pre-
specified 
outcomes 
reported 
Sample Size 
Sample size 
reached 
Rogers, 
2017 
LOW  
Complete 
randomisation 
schedule 
 
HIGH 
Neither 
subjects nor 
providers 
blinded due to 
structure of 
design 
HIGH 
Neither 
providers nor 
researchers 
blinded due to 
structure of 
design 
LOW  
All subjects 
accounted for 
LOW  
 All pre-
specified 
outcomes 
reported 
Sample size 
Sample size 
reached 
Denvir, 2016 LOW  
crossover 
design 1:1 
Random 
permuted 
blocks 
HIGH 
Neither 
subjects nor 
providers 
blinded due to 
structure of 
design 
UNCLEAR 
Not stated who 
recorded/collec
ted data 
LOW  
All subjects 
accounted for 
LOW  
All pre-
specified 
outcomes 
reported 
Sample size 
Sample size 
reached 
Only 2 
providers  
(1x cardiologist 
1x NP) 
Brannstrom, 
2014 
LOW 
Envelopes in 
blocks of 20  
HIGH 
Neither 
subjects nor 
providers 
blinded due to 
structure of 
design 
HIGH 
Neither 
providers nor 
researchers 
blinded due to 
structure of 
design 
LOW  
All subjects 
accounted for 
LOW  
All pre-
specified 
outcomes 
reported 
Sample size  
Sample size 
reached 
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Online Table 2. Quality appraisal observational studies 
STUDY COHORT 
RECRUITED IN 
ACCEPTABLE 
WAY? 
EXPOSURE 
MEASURED TO 
DECREASE 
BIAS? 
OUTCOME 
MEASURED TO 
DECREASE 
BIAS? 
IDENTIFIED ALL 
CONFOUNDERS
? 
RESULTS? GENERALISABLE
? 
Schellinger 
et al, 2011 
YES 
Multiple 
pathways 
YES 
Documented 
discussions 
YES 
Objective 
measures 
NO 
ACP done in 
usual care, 
contribution of 
co-morbidity 
etc. 
Reduced 
significance 
likely due to 
short follow up. 
Increased use 
hospice strong 
YES 
Shows 
achievable 
model 
Agrees with 
other data 
Johnson et 
al, 2012 
YES 
All referrals to 
HFNP 
YES 
Defined each 
service 
YES 
Objective 
measures 
NO 
ACP skills of GP, 
role of co-
morbidities 
Results 
comparisons 
between two 
groups. 
  
YES 
Shows two 
practice 
models.  
Follow up/lack 
of data may 
have reduced 
statistical 
significant 
results 
McAlister 
et al, 2015 
NO 
Selection 
limited by 
eligibility 
criteria for 
EFFECT trial so 
may not be 
representative 
of patient  
population 
YES 
All classified by 
set DNR 
criteria, 
although 
rudimentary 
and lacks 
further 
categorisation 
YES 
Objective 
measures 
NO 
Role of 
different teams 
to engage in 
ACP 
Community 
supports 
Admissions to 
other hospitals 
Results good 
Narrow CI, 
Odds ratio for 
30 day 
mortality from 
time of 
admission 
NO 
Selection 
restricted by 
EFFECT trial 
eligibility 
However, 
supports other 
data 
 
Butler et 
al, 2015 
YES 
However, 
coding errors 
for HF could 
occur 
YES  
ACP not on 
E.H.R found to 
be minimal  
YES 
Objective 
measures 
NO 
Many 
confounders 
discussed, but 
other include 
co-morbidity, 
home services  
Increased 
discharge to 
hospice strong 
data 
 
YES 
Cohort 
generalizable 
Supports other 
data  
Low uptake ACP 
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Online Table 3: OVID MEDLINE SEARCH: (23/3/17) 
Search Searches Results Annotation 
#1 exp Heart Failure/  103111  
#2 Systolic heart failure.mp or Heart Failure, Systolic/ 2137  
#3 Diastolic heart failure.mp or exp Heart Failure, Diastolic/  1429  
#4 Ventricular Dysfunction.mp or exp Ventricular Dysfunction/ 39694  
#5 Ventricular dysfunction left.mp or exp Ventricular 
Dysfunction, Left/ 
26558  
#6 Ventricular dysfunction right.mp or exp Ventricular 
dysfunction, Right/ 
4750  
#7 Cardiac failure.mp 10507  
#8 CCF.mp 1099  
#9 HF.mp 25569  
#10 exp Defibrillators 15821  
#11 ICD.mp 23607  
#12 LHF.mp 76  
#13 RHF.mp 404  
#14 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 
13 
186604 POPULATION 
#15 Advance care planning.mp or exp Advance care planning/ 8324  
#16 Resuscitation orders.mp or exp Resuscitation orders/ 3545  
#17 Anticipatory care plan*.mp 15  
#18 Living will.mp or exp Living Wills/ 2017  
#19 Advance directive.mp or exp Advance directives/ 7034  
#20 Medical directive.mp 53  
#21 End of life plan.mp 134  
#22 End of life discussion.mp 43  
#23 Medical treatment order.mp 2  
#24 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 11674 INTERVENTION 
#25 14 and 24 211  
#26 Limit 25 to “all adult (19 plus years)” 135  
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